EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy

Chunru Yang, Cheng Xiao, Zerui Ding, Xiaojun Zhai, Jieying Liu, Miao Yu

International Journal of Molecular Sciences · 26.06.2024 · 25 (13) · 7008

DOI: 10.3390/ijms25137008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.06.2024. Verfasst von Chunru Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endocrinology National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Me…. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Mitophagy, Protein Kinases, Canagliflozin. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Fund, Bethune and Merck fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic cardiomyopathy (DCM) is a major determinant of mortality in diabetic populations, and the potential strategies are insufficient. Canagliflozin has emerged as a potential cardioprotective agent in diabetes, yet its underlying molecular mechanisms remain unclear. We employed a high-glucose challenge (60 mM for 48 h) in vitro to rat cardiomyocytes (H9C2), with or without canagliflozin treatment (20 µM). In vivo, male C57BL/6J mice were subjected to streptozotocin and a high-fat diet to induce diabetes, followed by canagliflozin administration (10, 30 mg·kg−1·d−1) for 12 weeks. Proteomics and echocardiography were used to assess the heart. Histopathological alterations were assessed by the use of Oil Red O and Masson’s trichrome staining. Additionally, mitochondrial morphology and mitophagy were analyzed through biochemical and imaging techniques. A proteomic analysis highlighted alterations in mitochondrial and autophagy-related proteins after the treatment with canagliflozin. Diabetic conditions impaired mitochondrial respiration and ATP production, alongside decreasing the related expression of the PINK1-Parkin pathway. High-glucose conditions also reduced PGC-1α-TFAM signaling, which is responsible for mitochondrial biogenesis. Canagliflozin significantly alleviated cardiac dysfunction and improved mitochondrial function both in vitro and in vivo. Specifically, canagliflozin suppressed mitochondrial oxidative stress, enhancing ATP levels and sustaining mitochondrial respiratory capacity. It activated PINK1-Parkin-dependent mitophagy and improved mitochondrial function via increased phosphorylation of adenosine monophosphate-activated protein kinase (AMPK). Notably, PINK1 knockdown negated the beneficial effects of canagliflozin on mitochondrial integrity, underscoring the critical role of PINK1 in mediating these protective effects. Canagliflozin fosters PINK1-Parkin mitophagy and mitochondrial function, highlighting its potential as an effective treatment for DCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesMitophagyProtein KinasesCanagliflozinDiabetes Mellitus, ExperimentalMice, Inbred C57BLUbiquitin-Protein LigasesAnimalsMaleMiceRatsMyocytes, CardiacOxidative StressMitochondriaCell LineSignal TransductionDiet, High-FatPTEN-Induced Putative Kinase

Stichwörter der Autor:innen

diabetic cardiomyopathymitochondrial biogenesismitochondrial dysfunctionmitophagysodium-glucose co-transporter-2 inhibitor

Substanzen

Protein KinasesCanagliflozinUbiquitin-Protein LigasesPTEN-Induced Putative Kinaseparkin protein

Autor:innen und Institutionen

  • Key Laboratory of Endocrinology National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
  • Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Pe…

Förderung

  • National High Level Hospital Clinical Research Fund
  • Bethune and Merck fund
  • National Natural Science Foundation of China
  • ational Key Research and Development Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Yang, C., Xiao, C., Ding, Z., Zhai, X., Liu, J., & Yu, M. (2024). Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy. International Journal of Molecular Sciences, 25(13), 7008. https://doi.org/10.3390/ijms25137008

Vancouver

Yang C, Xiao C, Ding Z, Zhai X, Liu J, Yu M. Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy. International Journal of Molecular Sciences. 2024;25(13):7008. doi:10.3390/ijms25137008

BibTeX
@article{Yang2024,
  author = {Yang, Chunru and Xiao, Cheng and Ding, Zerui and Zhai, Xiaojun and Liu, Jieying and Yu, Miao},
  title = {Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {13},
  pages = {7008},
  doi = {10.3390/ijms25137008}
}
Kostenlos starten →